Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy

  • Zogenix Inc ZGNX has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS).
  • Data showed that fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures. 
  • A total of 247 patients entered the OLE study. During the treatment period, the median reduction in drop seizure frequency was 39.4% at 3 months and 51.8% for those patients assessed at months 10 to 12. 
  • Fintepla was generally well tolerated in the long-term trial with no observed valvular heart disease or pulmonary hypertension.
  • One patient death occurred; the cause was reported as aspiration pneumonia and was considered unrelated to the study drug.
  • Related Content: Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder.
  • Price Action: ZGNX stock is up 1.39% at $15.29 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsLennox-Gastaut syndrome
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!